Review anchor
Tyrosine-protein phosphatase non-receptor type 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Tyrosine-protein phosphatase non-receptor type 1
CHEMBL335
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein phosphatase non-receptor type 1 as ChEMBL target CHEMBL335, mapped to UniProt P18031. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL335
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18031
Tyrosine-protein phosphatase non-receptor type 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Tyrosine-protein phosphatase non-receptor type 1 matters
Tyrosine-protein phosphatase non-receptor type 1 is reviewed as Tyrosine-protein phosphatase non-receptor type 1 (UniProt P18031); the current evidence base includes 8 approved drugs, 5893 compounds, and 1137 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Tyrosine-protein phosphatase non-receptor type 1
Tyrosine-protein phosphatase non-receptor type 1 Sequence length is 435 aa.
Review this target as Tyrosine-protein phosphatase non-receptor type 1, mapped to UniProt P18031. Sequence length is 435 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P18031
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 5893 compounds, and 1137 assays for this target. The dominant activity type is IC50. CHEMBL444092 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL444092 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Tyrosine-protein phosphatase non-receptor type 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P18031, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5893
Total Compounds
1137
Total Assays
8
Approved Drugs
IC50: 4802.0, KI: 992.0, EC50: 1.0, KD: 68.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL444092
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL430266
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL4524071
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL5619806
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL244563
|
9.2 | Ki | — |
Source Header